Phase II clinical trial of combination of personalized peptide vaccination, Cyclophosphamide and Imiquimod for advanced Pancreatic cancer patients who failed standard therapy.
Phase 2
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000011593
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded: 1)Patients with severe symptoms(active and severe infectious disease, circulatory disease, respiratory dusease, kidney disease, immunodeficuency, disease of coagulation. 2)Patients with the past history pf severe allergic reactions. 3)(Females) Patients who are during pregnancy, lactation expectant, and desiring future fertility. (Males) Patients do not accept contraception during the 1st vaccination to 70 days after the last vaccination. 4)Patients who are judged inappropriate for the clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method